Improving Access to Trikafta for Cystic Fibrosis Patients in South Africa

By João L. Carapinha

December 16, 2024

The Competition Commission of South Africa recently published a media statement on cystic fibrosis medication access – Trikafta. This article highlights improvements in access to Trikafta, a critical medication for cystic fibrosis patients. Access to Trikafta has been primarily enhanced through the mechanisms established by Vertex Pharmaceuticals which has passed a review by the Competition Commission of South Africa.

Section 21 of the Medicines and Related Substances Act

– Section 21 allows SAHPRA to authorize the sale of unregistered medicines in South Africa under certain conditions. This provision enables registered medical practitioners to apply for approval to use unregistered medicines, such as Trikafta, for individual patients.
– In the context of Trikafta, Vertex has committed to making this medication available through Section 21. This approach allows patients in South Africa to access Trikafta even if it is not fully registered with SAHPRA.

Patient Access Program and Financial Assistance

– Vertex launched a patient assistance program, managed by an NGO, to reduce financial burdens on eligible patients. This initiative ensures that some cystic fibrosis patients can access Trikafta at no cost.
– Eligible patients under specific medical schemes can access Trikafta for free through financial assistance. This includes support from top-end medical plans offered by Discovery Health.

Impact on Access to Medicine Initiatives

– The decision by the Competition Commission to accept Vertex’s undertakings and non-refer the complaint is viewed as a positive outcome for access to medicine initiatives in South Africa. It guarantees that patients can access life-changing medications like Trikafta locally, at a more affordable price than before.
– The local distribution of Trikafta, starting in April 2024, significantly enhances the medication’s accessibility. Patients will no longer have to import it from other countries, aligning with public interest and the objectives of the Competition Act.

Conclusion

Overall, the initiatives undertaken by Vertex, reviewed by the Competition Commission, represent a marked improvement in access to Trikafta for cystic fibrosis patients in South Africa. The implementation of Section 21 authorizations and patient assistance programs makes this critical medication more accessible and affordable, which is a positive advancement for access to medicine initiatives in the country.

Reference url

Recent Posts

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

tislelizumab NSCLC treatment
        

Early Benefit Assessment of Tislelizumab NSCLC Treatment: Insights and Implications

🧐 How is the evolving treatment landscape for NSCLC affecting patient access to tislelizumab?

The German Federal Joint Committee (G-BA) has launched an early benefit assessment for tislelizumab as a second-line treatment for adults with advanced NSCLC. This assessment notably focuses on PD-L1 negative patients and highlights the need for additional data to substantiate its value amidst a shifting emphasis on first-line immunotherapy.

Explore the nuances of this assessment and its implications for future research and market access in the full article.

#SyenzaNews #oncology #MarketAccess

colorectal cancer screening
    

Advances in Colorectal Cancer Screening: Access and Cost

🚀 Is blood-based screening redefining colorectal cancer detection?

The Shield blood test offers a non-invasive alternative to colonoscopy—boosting screening uptake, but raising questions around effectiveness and value.

🔍 Discover how this innovation could reshape patient care, payer strategy, and health system costs.

#SyenzaNews #HealthcareInnovation #CostEffectiveness #DigitalTransformation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.